NCT02115113View on ClinicalTrials.gov

REnal Function in Liver Transplantation: Everolimus With Calcineurin Inhibitor (CNI)-Sparing sTrategy

PHASE3CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

March 28, 2014

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions
Liver Transplantation
Interventions
DRUG

Everolimus

Commercial product labeled according to local requirements will be provided as 0.25 mg and 0.75 mg tablets for oral administration.

DRUG

Tacrolimus

Commercial product labeled according to local requirements will be provided as 0.5 mg, 1.0 mg and 5.0 mg capsules for oral administration.

Trial Locations (14)

10126

Novartis Investigative Site, Torino

20122

Novartis Investigative Site, Milan

24127

Novartis Investigative Site, Bergamo

33100

Novartis Investigative Site, Udine

35128

Novartis Investigative Site, Padua

37126

Novartis Investigative Site, Verona

40138

Novartis Investigative Site, Bologna

41124

Novartis Investigative Site, Modena

56124

Novartis Investigative Site, Pisa

60126

Novartis Investigative Site, Ancona

70124

Novartis Investigative Site, Bari

80132

Novartis Investigative Site, Napoli

00144

Novartis Investigative Site, Roma

00168

Novartis Investigative Site, Roma

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY